Leen Kawas - Net Worth and Insider Trading

Leen Kawas Net Worth

The estimated net worth of Leen Kawas is at least $1 Million dollars as of 2024-12-28. Leen Kawas is the 10% Owner of Eiger BioPharmaceuticals Inc and owns about 146,381 shares of Eiger BioPharmaceuticals Inc (EIGRQ) stock worth over $1 Million. Details can be seen in Leen Kawas's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Leen Kawas has not made any transactions after 2023-10-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Leen Kawas

To

Leen Kawas Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Leen Kawas owns 2 companies in total, including Athira Pharma Inc (ATHA) , and Eiger BioPharmaceuticals Inc (EIGRQ) .

Click here to see the complete history of Leen Kawas’s form 4 insider trades.

Insider Ownership Summary of Leen Kawas

Ticker Comapny Transaction Date Type of Owner
ATHA Athira Pharma Inc 2020-09-17 director & 10 percent owner & President & CEO
EIGRQ Eiger BioPharmaceuticals Inc 2023-10-31 10 percent owner

Leen Kawas Latest Holdings Summary

Leen Kawas currently owns a total of 1 stock. Leen Kawas owns 146,381 shares of Eiger BioPharmaceuticals Inc (EIGRQ) as of October 31, 2023, with a value of $1 Million.

Latest Holdings of Leen Kawas

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
EIGRQ Eiger BioPharmaceuticals Inc 2023-10-31 146,381 8.50 1,244,239

Holding Weightings of Leen Kawas


Leen Kawas Form 4 Trading Tracker

According to the SEC Form 4 filings, Leen Kawas has made a total of 1 transactions in Eiger BioPharmaceuticals Inc (EIGRQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Eiger BioPharmaceuticals Inc is the acquisition of 811 shares on October 31, 2023, which cost Leen Kawas around $6,326.

Insider Trading History of Leen Kawas

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Leen Kawas Trading Performance

GuruFocus tracks the stock performance after each of Leen Kawas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Leen Kawas is -12.01%. GuruFocus also compares Leen Kawas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Leen Kawas within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Leen Kawas's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Leen Kawas

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 30.27 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 20.71 LIMIT LIMIT LIMIT LIMIT LIMIT

Leen Kawas Ownership Network

Ownership Network List of Leen Kawas

No Data

Ownership Network Relation of Leen Kawas

Insider Network Chart

Leen Kawas Owned Company Details

What does Athira Pharma Inc do?

Who are the key executives at Athira Pharma Inc?

Leen Kawas is the director & 10 percent owner & President & CEO of Athira Pharma Inc. Other key executives at Athira Pharma Inc include See Below Andrew Gengos , Chief Operating Officer Mark James Litton , and Vice President of Discovery Kevin Church .

Athira Pharma Inc (ATHA) Insider Trades Summary

Over the past 18 months, Leen Kawas made no insider transaction in Athira Pharma Inc (ATHA). Other recent insider transactions involving Athira Pharma Inc (ATHA) include a net sale of 14,672 shares made by Mark James Litton , a net sale of 7,349 shares made by Rachel Lenington , and a net sale of 7,349 shares made by Mark Worthington .

In summary, during the past 3 months, insiders sold 0 shares of Athira Pharma Inc (ATHA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 36,787 shares of Athira Pharma Inc (ATHA) were sold and 648,086 shares were bought by its insiders, resulting in a net purchase of 611,299 shares.

Athira Pharma Inc (ATHA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Athira Pharma Inc Insider Transactions

No Available Data

Leen Kawas Mailing Address

Above is the net worth, insider trading, and ownership report for Leen Kawas. You might contact Leen Kawas via mailing address: 4000 Mason Road, Suite 300, Box 352141, Seattle Wa 98195-2141.

Discussions on Leen Kawas

No discussions yet.